Literature DB >> 16988763

Negative regulation of intracellular hepatitis C virus replication by interferon regulatory factor 3.

Tsuyoshi Yamashiro1, Naoya Sakamoto, Masayuki Kurosaki, Nobuhiko Kanazawa, Yoko Tanabe, Mina Nakagawa, Cheng-Hsin Chen, Yasuhiro Itsui, Tomoyuki Koyama, Yoshie Takeda, Shinya Maekawa, Nobuyuki Enomoto, Hiroshi Sakugawa, Mamoru Watanabe.   

Abstract

BACKGROUND: Interferon regulatory factor (IRF)-3 plays an important role in initiating cellular interferon-stimulated gene-mediated antiviral responses. In the present study, we evaluated the effects of IRF-3 expression and activation on intracellular hepatitis C virus (HCV) replication using an HCV replicon system.
METHODS: An HCV replicon was constructed that expressed a neomycin-selectable chimeric firefly luciferase reporter protein. A small interfering (si) RNA oligonucleotide directed against IRF-3 mRNA was designed and synthesized. A eukaryote expression plasmid vector was constructed that expressed IRF-3 mRNA under control of the cytomegalovirus early promoter/enhancer. To evaluate transcriptional activity of the interferon-stimulated genes, a reporter vector was used that expressed firefly luciferase under control of the interferon-stimulated response element (ISRE).
RESULTS: The baseline expression of IRF-3 did not significantly differ between cells with and without expression of the replicon. Transfection of an IRF-3 expression plasmid into the cells raised the ISRE-luciferase activities. The increase of ISRE activity was significantly more potent in the replicon-expressing cells than in cells without replicon expression. Concomitantly, the overexpression of IRF-3 suppressed HCV replication levels. In contrast, siRNA knockdown of IRF-3 suppressed ISRE activity by 38% +/- 2%. Interestingly, the suppression of IRF-3 resulted in a significant increase of HCV replication, by up to twofold, depending on the IRF-3 suppression levels.
CONCLUSIONS: IRF-3 negatively regulated intracellular HCV replication, and was partially activated in cells that expressed the HCV replicon. Thus, IRF-3 is a key molecule controlling HCV replication through modulation of host interferon gene responses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16988763     DOI: 10.1007/s00535-006-1842-x

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  33 in total

1.  Noncytopathic bovine viral diarrhea virus inhibits double-stranded RNA-induced apoptosis and interferon synthesis.

Authors:  M Schweizer; E Peterhans
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Interferon alfa subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls.

Authors:  Y Castelruiz; E Larrea; P Boya; M P Civeira; J Prieto
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

3.  Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction.

Authors:  M Sato; H Suemori; N Hata; M Asagiri; K Ogasawara; K Nakao; T Nakaya; M Katsuki; S Noguchi; N Tanaka; T Taniguchi
Journal:  Immunity       Date:  2000-10       Impact factor: 31.745

Review 4.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 5.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

6.  The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses.

Authors:  Mitsutoshi Yoneyama; Mika Kikuchi; Takashi Natsukawa; Noriaki Shinobu; Tadaatsu Imaizumi; Makoto Miyagishi; Kazunari Taira; Shizuo Akira; Takashi Fujita
Journal:  Nat Immunol       Date:  2004-06-20       Impact factor: 25.606

7.  IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway.

Authors:  Katherine A Fitzgerald; Sarah M McWhirter; Kerrie L Faia; Daniel C Rowe; Eicke Latz; Douglas T Golenbock; Anthony J Coyle; Sha-Mei Liao; Tom Maniatis
Journal:  Nat Immunol       Date:  2003-05       Impact factor: 25.606

Review 8.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

9.  Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs.

Authors:  Michael Frese; Verena Schwärzle; Kerstin Barth; Nicole Krieger; Volker Lohmann; Sabine Mihm; Otto Haller; Ralf Bartenschlager
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

10.  Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons.

Authors:  Robert E Lanford; Bernadette Guerra; Helen Lee; Devron R Averett; Brad Pfeiffer; Deborah Chavez; Lena Notvall; Catherine Bigger
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  3 in total

1.  Understanding the precise function of interferon regulatory factor 3 in hepatitis C virus replication will lead to a new strategy for therapy.

Authors:  Yoichi Hiasa; Morikazu Onji
Journal:  J Gastroenterol       Date:  2006-08       Impact factor: 7.527

2.  Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122.

Authors:  Liang-Tzung Lin; Ryan S Noyce; Tram N Q Pham; Joyce A Wilson; Gary R Sisson; Thomas I Michalak; Karen L Mossman; Christopher D Richardson
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

3.  Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells.

Authors:  Yuki Nishimura-Sakurai; Naoya Sakamoto; Kaoru Mogushi; Satoshi Nagaie; Mina Nakagawa; Yasuhiro Itsui; Megumi Tasaka-Fujita; Yuko Onuki-Karakama; Goki Suda; Kako Mishima; Machi Yamamoto; Mayumi Ueyama; Yusuke Funaoka; Takako Watanabe; Seishin Azuma; Yuko Sekine-Osajima; Sei Kakinuma; Kiichiro Tsuchiya; Nobuyuki Enomoto; Hiroshi Tanaka; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2009-12-12       Impact factor: 7.527

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.